Eckhard Niemeier is a highly experienced deal maker in the life science sector, drawing on almost 20 years of experience in corporate development, corporate strategy and financial analysis and valuation.
Before joining UNION in June 2021, Eckhard was SVP, Head of Business Development and Portfolio Management at Pieris Pharmaceuticals (Nasdaq:PIRS), where he was responsible for all business and corporate development activities including establishing strategic partnerships with AstraZeneca, Roche/Genentech, Seagen and Servier.
Prior to joining Pieris, Eckhard held senior business development positions at Gruenenthal Pharma, where he was responsible for international licensing activities across all stages of drug development, and MorphoSys AG, where he negotiated multiple product and technology licensing deals. Eckhard began his career at McKinsey & Company in their Healthcare Practice.
Eckhard holds a M.Sc. in Biotechnology and completed his thesis in Molecular Biology at Human Genome Sciences, now part of GSK.
